Virtual screening (VS) is a computational practice applied in drug discovery research. VS is popularly applied in a computer-based search for new lead molecules based on molecular similarity searching. In chemical databases similarity searching is used to identify molecules that have similarities to a user-defined reference structure and is evaluated by quantitative measures of intermolecular structural similarity. Among existing approaches, 2D fingerprints are widely used. The similarity of a reference structure and a database structure is measured by the computation of association coefficients. In most classical similarity approaches, it is assumed that the molecular features in both biological and non-biologically-related activity carry the same weight. However, based on the chemical structure, it has been found that some distinguishable features are more important than others. Hence, this difference should be taken consideration by placing more weight on each important fragment. The main aim of this research is to enhance the performance of similarity searching by using multiple descriptors. In this paper, a deep learning method known as deep belief networks (DBN) has been used to reweight the molecule features. Several descriptors have been used for the MDL Drug Data Report (MDDR) dataset each of which represents different important features. The proposed method has been implemented with each descriptor individually to select the important features based on a new weight, with a lower error rate, and merging together all new features from all descriptors to produce a new descriptor for similarity searching. Based on the extensive experiments conducted, the results show that the proposed method outperformed several existing benchmark similarity methods, including Bayesian inference networks (BIN), the Tanimoto similarity method (TAN), adapted similarity measure of text processing (ASMTP) and the quantum-based similarity method (SQB). The results of this proposed multi-descriptor-based on Stack of deep belief networks method (SDBN) demonstrated a higher accuracy compared to existing methods on structurally heterogeneous datasets.
Determining and modeling the possible behaviour and actions of molecules requires investigating the basic structural features and physicochemical properties that determine their behaviour during chemical, physical, biological, and environmental processes. Computational approaches such as machine learning methods are alternatives to predicting the physiochemical properties of molecules based on their structures. However, the limited accuracy and high error rates of such predictions restrict their use. In this paper, a novel technique based on a deep learning convolutional neural network (CNN) for the prediction of chemical compounds’ bioactivity is proposed and developed. The molecules are represented in the new matrix format Mol2mat, a molecular matrix representation adapted from the well-known 2D-fingerprint descriptors. To evaluate the performance of the proposed methods, a series of experiments were conducted using two standard datasets, namely the MDL Drug Data Report (MDDR) and Sutherland, datasets comprising 10 homogeneous and 14 heterogeneous activity classes. After analysing the eight fingerprints, all the probable combinations were investigated using the five best descriptors. The results showed that a combination of three fingerprints, ECFP4, EPFP4, and ECFC4, along with a CNN activity prediction process, achieved the highest performance of 98% AUC when compared to the state-of-the-art ML algorithms NaiveB, LSVM, and RBFN.
The concept of molecular similarity has been commonly used in rational drug design, where structurally similar molecules are examined in molecular databases to retrieve functionally similar molecules. The most used conventional similarity methods used two-dimensional (2D) fingerprints to evaluate the similarity of molecules towards a target query. However, these descriptors include redundant and irrelevant features that might impact the performance of similarity searching methods. Thus, this study proposed a new approach for identifying the important features of molecules in chemical datasets based on the representation of the molecular features using Autoencoder (AE), with the aim of removing irrelevant and redundant features. The proposed approach experimented using the MDL Data Drug Report standard dataset (MDDR). Based on experimental findings, the proposed approach performed better than several existing benchmark similarity methods such as Tanimoto Similarity Method (TAN), Adapted Similarity Measure of Text Processing (ASMTP), and Quantum-Based Similarity Method (SQB). The results demonstrated that the performance achieved by the proposed approach has proven to be superior, particularly with the use of structurally heterogeneous datasets, where it yielded improved results compared to other previously used methods with the similar goal of improving molecular similarity searching.
Molecular similarity is a pervasive concept in drug design. The basic idea underlying molecular similarity is the similar property principle, which states that structurally similar molecules will exhibit similar physicochemical and biological properties. In this paper, a new graph-based molecular descriptor (GBMD) is introduced. The GBMD is a new method of obtaining a rough description of 2D molecular structure in textual form based on the canonical representations of the molecule outline shape and it allows rigorous structure specification using small and natural grammars. Simulated virtual screening experiments with the MDDR database show clearly the superiority of the graph-based descriptor compared to many standard descriptors (ALOGP, MACCS, EPFP4, CDKFP, PCFP, and SMILE) using the Tanimoto coefficient (TAN) and the basic local alignment search tool (BLAST) when searches were carried.
1 January 2023 in International Journal of Data Mining, Modelling and Management